Author: Tang, Wen-Ruei; Hsu, Che-Wei; Lee, Chia-Chi; Huang, Wei-Li; Lin, Chia-Ying; Hsu, Ya-Ting; Chang, Chen; Tsai, Meng-Ta; Hu, Yuâ€Ning; Hsu, Chih-Hsin; Chen, Po-Lin; Chow, Nan-Haw; Roan, Jun-Neng
Title: A Case Report of Post-transplant lymphoproliferative disorder following AstraZeneca COVID-19 vaccine in a heart transplant recipient Cord-id: w4m9agd0 Document date: 2021_9_30
ID: w4m9agd0
Snippet: We report a case of a heart transplant recipient who presented with a rapidly growing Epstein-Barr virus (EBV)-positive, diffuse large B-cell lymphoma seven days after receiving the first dose of the ChAdOx1 nCoV-19 vaccine. Because of the atypical radiological presentation, the initial tentative diagnosis was a mediastinal abscess. This observation indicates a potential risk of EBV reactivation after COVID-19 vaccination, which might lead to or aggravate the presentation of post-transplant lymp
Document: We report a case of a heart transplant recipient who presented with a rapidly growing Epstein-Barr virus (EBV)-positive, diffuse large B-cell lymphoma seven days after receiving the first dose of the ChAdOx1 nCoV-19 vaccine. Because of the atypical radiological presentation, the initial tentative diagnosis was a mediastinal abscess. This observation indicates a potential risk of EBV reactivation after COVID-19 vaccination, which might lead to or aggravate the presentation of post-transplant lymphoproliferative disorder in transplantation patients. Transplant surgeons should be aware of the potential immunomodulatory effects of COVID-19 vaccination.
Search related documents:
Co phrase search for related documents- lung transplant and lymphoid disorder: 1
Co phrase search for related documents, hyperlinks ordered by date